Physicians Treating Few Patients With Buprenorphine

Share this content:
Physicians Treating Few Patients With Buprenorphine
Physicians Treating Few Patients With Buprenorphine

WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- For buprenorphine prescribers, the monthly patient census is 13 patients, according to a research letter published in the Sept. 20 issue of the Journal of the American Medical Association.

Bradley D. Stein, M.D., Ph.D., from the RAND Corporation in Pittsburgh, and colleagues analyzed data from the Symphony Health Solutions' Integrated Dataverse for seven states with the most buprenorphine-waivered physicians, who are restricted in the number of patients with opioid disorders that they can treat concurrently. The number of patient episodes (starting with the first observed buprenorphine claim) for each provider were summed to calculate monthly patient census.

The researchers identified 3,234 buprenorphine prescribers with 245,016 patients receiving a new prescription of buprenorphine. The monthly patient census for prescribers was 13 patients, with median episode duration of 53 days. Overall, 22, 49, 20, and 9 percent of prescribers had monthly censuses of one to three, four to 30, 31 to 75, and more than 75 patients, respectively. In years subsequent to 2010, there was an increase in patient census. The lowest census was seen in California and the highest in Massachusetts and Pennsylvania.

"Strategies to help current prescribers treat more patients safely and effectively could complement policy initiatives designed to increase access to treatment by increasing patient limits and number of waivered prescribers," the authors write.

One author disclosed financial ties to the pharmaceutical industry; two authors disclosed ties to the publishing industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »